Maxygen, Inc.

Maxygen Holdings Ltd.

Roche Palo Alto LLC

Fluxome Sciences A/s

Torben Lauesgaard Nissen

Phillip A Patten

Sridhar Viswanathan

Stefan Seeber

Kim Vilbour Andersen

Sridhar Govindarajan

Stephan Fischer

Ralf Schumacher

Christian Hansen

Jan Moller Mikkelsen

Anne Vogt

Harald Kropshofer

Andreas Schaubmar

Hans Thalsgaard Schambye

Hans Koll

Roberto Falkenstein

Adelbert Grossmann

Friederike Hesse

Jens Bredal Nielsen

Morten C Kielland-Brandt

Hans Thalsgard Schambye

Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.

G-CSF conjugates

The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

Interferon-alpha polypeptides and conjugates

Growing community of inventors

London, United Kingdom

Torben Lauesgaard Nissen